NXT-211

N/A

Report date: 2025/11/24 17:58:16

Base Information

Drug NameNXT-211

Drug Alias NameRadiolabelled anti-isoferritin antibodyradiolabeled anti-ferritin IgG antibodiesanti-ferritin IgG antibodiesAnti-ferritin antibody-Y90NXT-211

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionIonising radiation emittersRadionuclide imaging enhancers

TargetsFerritin

Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsHodgkin Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesNextherapeutics

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNextherapeutics

Active IndicationsN/A

Inactive IndicationsCarcinoma, Non-Small-Cell LungPancreatic NeoplasmsHodgkin Disease

Other Information

ATC CodeN/A